An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
Thomas E. Witzig,Julie M. Vose,Pier Luigi Zinzani,Craig B. Reeder,Rena Buckstein,Jonathan Polikoff,R. Bouabdallah,Corinne Haioun,H. Tilly,Pingshan Guo,Dennis Pietronigro,Annette Ervin-Haynes,Myron S. Czuczman +12 more
Reads0
Chats0
TLDR
Lenalidomide is well tolerated and produces durable responses in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.About:
This article is published in Annals of Oncology.The article was published on 2011-07-01 and is currently open access. It has received 367 citations till now. The article focuses on the topics: Lenalidomide & Diffuse large B-cell lymphoma.read more
Citations
More filters
Journal ArticleDOI
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.
Laurie H. Sehn,Randy D. Gascoyne +1 more
TL;DR: It will be necessary to prioritize drugs that affect key driver pathways and to combine them rationally to optimize their benefit and improve prognostication and the availability of predictive biomarkers will be crucial to allow for the possibility of individualized risk-adapted therapy.
Journal ArticleDOI
The tumour microenvironment in B cell lymphomas
David W. Scott,Randy D. Gascoyne +1 more
TL;DR: A fundamental understanding of interactions between tumour cells and non-malignant cells gives insight into the pathogenesis of most B cell lymphomas and identifies novel therapeutic opportunities for targeting oncogenic pathways, both now and in the future.
Journal ArticleDOI
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Bruce D. Cheson,Stephen M. Ansell,Lawrence H. Schwartz,Leo I. Gordon,Ranjana H. Advani,Heather A. Jacene,Axel Hoos,Sally F. Barrington,Philippe Armand +8 more
TL;DR: A workshop was convened to provide provisional recommendations to modify current response criteria in patients receiving immunomodulatory agents in clinical trials, and the term "indeterminate response" was introduced to identify such lesions until confirmed as flare/pseudo-progression or true PD by either biopsy or subsequent imaging.
Journal ArticleDOI
Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study
Grzegorz S. Nowakowski,Betsy LaPlant,William R. Macon,Craig B. Reeder,James M. Foran,Garth D. Nelson,Carrie A. Thompson,Candido E. Rivera,David J. Inwards,Ivana N. Micallef,Patrick B. Johnston,Luis F. Porrata,Stephen M. Ansell,Randy D. Gascoyne,Thomas M. Habermann,Thomas E. Witzig +15 more
TL;DR: R2CHOP shows promising efficacy in DLBCL and the addition of lenalidomide appears to mitigate a negative impact of non-GCB phenotype on patient outcome.
Journal ArticleDOI
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
Andre Goy,Rajni Sinha,Michael Williams,Sevgi Kalayoglu Besisik,Johannes Drach,Radhakrishnan Ramchandren,Lei Zhang,Sherri Cicero,Tommy Fu,Thomas E. Witzig +9 more
TL;DR: The MCL-001 study demonstrated durable efficacy of lenalidomide with a predictable safety profile in heavily pretreated patients with MCL who had all relapsed or progressed after or were refractory to bortezomib.
References
More filters
Journal ArticleDOI
Cancer Statistics, 2009
TL;DR: The most recent data on cancer incidence, mortality, and survival from the American Cancer Society (ACS) is presented in this paper, where the authors compare the three major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and in two major cancers sites in women (breast and colorectal) over a 15-year period.
Journal ArticleDOI
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
Bertrand Coiffier,Eric Lepage,Josette Brière,Raoul Herbrecht,Hervé Tilly,Reda Bouabdallah,Pierre Morel,Eric Van Den Neste,Gilles Salles,Philippe Gaulard,Felix Reyes,Pierre Lederlin,Christian Gisselbrecht +12 more
TL;DR: A randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma found the rate of complete response was significantly higher in the group that received CHOP plus r ituximabs than in thegroup that receivedCHOP alone.
Journal ArticleDOI
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Bruce D. Cheson,Sandra J. Horning,B Coiffier,Margaret A. Shipp,Richard I. Fisher,J Connors,T A Lister,Julie M. Vose,Antonio J. Grillo-Lopez,A Hagenbeek,F Cabanillas,D Klippensten,W Hiddemann,R A Castellino,Nancy L. Harris,James O. Armitage,W. D. Carter,Richard T. Hoppe,George P. Canellos +18 more
TL;DR: Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL), and two meetings were convened among United States and international lymphoma experts to develop a uniform set of criteria for assessing response in clinical trials.
Journal ArticleDOI
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
Thierry Philip,Cesare Guglielmi,Anton Hagenbeek,Riet Somers,H. Van der Lelie,Dominique Bron,Pieter Sonneveld,Christian Gisselbrecht,Jean-Yves Cahn,Jean Luc Harousseau +9 more
TL;DR: Treatment with high-dose chemotherapy and autologous bone marrow transplantation increases event-free and overall survival in patients with chemotherapy-sensitive non-Hodgkin's lymphoma in relapse.
Journal ArticleDOI
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
Thomas M. Habermann,Edie Weller,Vicki A. Morrison,Randy D. Gascoyne,Peter A. Cassileth,Jeffrey B. Cohn,Shaker R. Dakhil,Bruce A. Woda,Richard I. Fisher,Bruce A. Peterson,Sandra J. Horning +10 more
TL;DR: Rituximab administered as induction or maintenance with CHOP chemotherapy significantly prolonged FFS in older DLBCL patients, which are consistent with an additive effect of ritUXimab.
Related Papers (5)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh,Michael B. Eisen,R. Eric Davis,Izidore S. Lossos,Andreas Rosenwald,Jennifer C. Boldrick,Hajeer Sabet,Truc Tran,Xin Yu,John Powell,Liming Yang,Gerald E. Marti,Troy Moore,James I. Hudson,Li-Sheng Lu,David B. Lewis,Robert Tibshirani,Gavin Sherlock,Wing C. Chan,Timothy C. Greiner,Dennis D. Weisenburger,James O. Armitage,Roger A. Warnke,Ronald Levy,Wyndham H. Wilson,M. R. Grever,John C. Byrd,David Botstein,Patrick O. Brown,Louis M. Staudt +29 more
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more